Amazon Explores AI Content Marketplace With Media Publishers 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
TEMPLE CITY, Calif., Nov. 14, 2017 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) today announced that its Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim are scheduled to participate in the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at the Lotte New York Palace Hotel in New York, New York.
These representatives of the company will participate in a question-and-answer session with the host analyst beginning at approximately 8:00 a.m. ET.
A live webcast of the question and answer session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible at ir.fulgentgenetics.com beginning approximately one hour following the completion of the event.
About Fulgent Genetics
Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633, [email protected]
